Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

Efficacy of PP-01 in Mitigating Cannabis Withdrawal Symptoms in Adults With Cannabis Use Disorder

1. september 2026 oppdatert av: PleoPharma, Inc.

A Phase 3, Multicenter, Randomized, Double-Blind, Placebo and Active-Controlled Clinical Trial of Titrating Doses of PP-01 for the Mitigation of Cannabis Withdrawal Symptoms in Adults With Cannabis Use Disorder: Core Study With Safety Extension Phase

This study is a randomized, double-blind, placebo and active-controlled, multicenter trial conducted to evaluate whether PP-01 mitigates the withdrawal symptoms associated with discontinuing cannabis in participants with moderate to severe cannabis use disorder (CUD). Study participants will receive PP-01, nabilone, or placebo every day for 34 days. The total study duration will be approximately 78 days, including screening and a one-week inpatient stay. Following the initial inpatient portion of the study, participants will return to the clinic for six clinic visits and complete two telemedicine appointments. Participants will complete daily symptom diaries and other study-related questionnaires.

Participants who complete the core study may be eligible to participate in a repeat dosing extension study if they meet required criteria.

Studieoversikt

Status

Rekruttering

Forhold

Intervensjon / Behandling

Studietype

Intervensjonell

Registrering (Antatt)

420

Fase

  • Fase 3

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiekontakt

Studer Kontakt Backup

Studiesteder

  • Forente stater
    • Arkansas
      • Little Rock, Arkansas, Forente stater, 72211
        • Rekruttering
        • Woodland International Research Group, LLC
        • Hovedetterforsker:
          • George Konis, MD
      • Rogers, Arkansas, Forente stater, 72758
        • Rekruttering
        • Woodland Research Northwest, LLC
        • Hovedetterforsker:
          • Ryan Mahelona, MD
    • Connecticut
      • New Haven, Connecticut, Forente stater, 06519
        • Rekruttering
        • Yale Stress Center
        • Hovedetterforsker:
          • Rajita Sinha, PhD
    • Florida
      • DeLand, Florida, Forente stater, 32720
        • Rekruttering
        • University Clinical Research-DeLand, LLC d/b/a Accel Research Sites - DeLand Clinical Research Unit
        • Hovedetterforsker:
          • Bruce G. Rankin, DO
      • Hollywood, Florida, Forente stater, 33024
        • Rekruttering
        • Research Centers of America
        • Hovedetterforsker:
          • Edwin A. Gomez, MD
      • Largo, Florida, Forente stater, 33777
        • Rekruttering
        • Sandhill Research, LLC d/b/a Accel Research Sites - St. Pete - Largo Clinical Research Unit
        • Hovedetterforsker:
          • Rosario B. Hidalgo, MD
      • Tampa, Florida, Forente stater, 33613
        • Rekruttering
        • ForCare Clinical Research
        • Hovedetterforsker:
          • Marlene P. Hart, MD
      • West Palm Beach, Florida, Forente stater, 33407
        • Rekruttering
        • Neuroscience Research Institute
        • Hovedetterforsker:
          • Danesh Alam, MD
    • Georgia
      • Decatur, Georgia, Forente stater, 30030
        • Rekruttering
        • Sandhill Research, LLC d/b/a Accel Research Sites - NeuroStudies Clinical Research Unit 755
        • Hovedetterforsker:
          • Marshall L. Nash, MD, FAHA, CPI, FAPCR
      • Norcross, Georgia, Forente stater, 30092
        • Rekruttering
        • Evergreen Clinical Trials
        • Hovedetterforsker:
          • Dmitriy Pelishev, DO
      • Savannah, Georgia, Forente stater, 31405
        • Rekruttering
        • CenExel iResearch, LLC
        • Hovedetterforsker:
          • Nancy E. Backus, MD
    • Kentucky
      • Lexington, Kentucky, Forente stater, 40509
        • Rekruttering
        • AMR Clinical
        • Hovedetterforsker:
          • Peter Akpunonu, MD
    • Maryland
      • Baltimore, Maryland, Forente stater, 21228
        • Rekruttering
        • Maryland Psychiatric Research Center, University of Maryland School of Medicine
        • Hovedetterforsker:
          • David A Gorelick, MD, PhD
    • Nevada
      • Las Vegas, Nevada, Forente stater, 89121
        • Rekruttering
        • Oasis Clinical Research
        • Hovedetterforsker:
          • Stephen Tam, MD
    • New Jersey
      • Marlton, New Jersey, Forente stater, 08053
        • Rekruttering
        • Hassman Research Institute, LLC d/b/a CenExel Marlton, NJ
        • Hovedetterforsker:
          • Elan A. Cohen, PhD
    • New York
      • New York, New York, Forente stater, 10032
        • Rekruttering
        • The Research Foundation for Mental Hygiene/ New York State Psychiatric Institute
        • Hovedetterforsker:
          • John Mariani, MD
      • Staten Island, New York, Forente stater, 10314
        • Rekruttering
        • Richmond Behavioral Associates
        • Hovedetterforsker:
          • Romana Kulikova, MD
    • Ohio
      • North Canton, Ohio, Forente stater, 44720
        • Rekruttering
        • Neuro-Behavioral Clinical Research, Inc.
        • Hovedetterforsker:
          • Shishuka Malhotra, MD
    • South Carolina
      • North Charleston, South Carolina, Forente stater, 29405
        • Rekruttering
        • Coastal Carolina Research Center, LLC
        • Hovedetterforsker:
          • Elizabeth Perkins, MD
    • Tennessee
      • Knoxville, Tennessee, Forente stater, 37920
        • Rekruttering
        • AMR Clinical
        • Hovedetterforsker:
          • Jerry L. Punch, MD
    • Texas
      • Austin, Texas, Forente stater, 78754
        • Rekruttering
        • Community Clinical Research, Inc.
        • Hovedetterforsker:
          • David Brown, MD
      • Houston, Texas, Forente stater, 77043
        • Rekruttering
        • Memorial Hermann Village
        • Hovedetterforsker:
          • Dominick Stevan D'Aunno, MD

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

  • Voksen

Tar imot friske frivillige

Nei

Beskrivelse

Inclusion Criteria:

  1. Generally healthy adults between the ages of 18 and 55, inclusive.
  2. Meet DSM-5 diagnostic criteria for current moderate to severe CUD as confirmed by a licensed physician or psychologist or addiction medicine specialist.
  3. BMI within 18.0 to 38.0 kg/m2, inclusive.
  4. Female participants must not be pregnant or lactating. If of childbearing potential - the participant agrees to use an accepted contraceptive regimen.
  5. Male participants who are fertile and engage in sexual activity must agree to use a double barrier method (e.g., condom and spermicide) during the study and to not donate sperm for 90 days after the last dose of study medication.
  6. Be seeking and motivated to discontinue cannabis and to minimize withdrawal symptoms.
  7. Agree to not use cannabis or any product containing CBD, hemp derivatives, terpenes or any THC containing product including delta-8, delta-10, THC-A or any other cannabinoid-like product following Randomization and throughout the study duration.
  8. Meet DSM-5 Cannabis Withdrawal Criteria.
  9. Report heavy use of daily/near daily cannabis.
  10. Have a urine drug screen positive for THC/THC metabolite and have a negative result for all other illicit/excluded drugs and alcohol at Screening and Randomization.
  11. Capable of giving informed consent and stated willingness to comply with all study procedures including inpatient and weekly outpatient visits, daily evening video calls, restrictions, and availability for the duration of the study.
  12. Willing to be admitted to an inpatient clinic with overnight stays on Days 1 through 6 and return for all outpatient visits.
  13. Ability to take study drug capsules at approximately the same time each day.
  14. Have regular access to the internet and access to video/virtual capabilities for video calls by any means.
  15. Agree to not use any alcohol during the study.
  16. No plan to change current nicotine use.
  17. Ability to read, understand, and complete daily diaries.

Exclusion Criteria:

  1. Lifetime history of DSM-5 diagnosis of schizophrenia, schizoaffective disorder, or bipolar disorder.
  2. Current DSM-5 criteria for a psychiatric disorder that in the Investigator's judgment is unstable, would be disrupted by the study medication, or is likely to require new pharmacotherapy or psychotherapy during the study period. Individuals who are currently stable on psychotropic medication for at least 3 months may be included at the discretion of the Investigator's judgement.
  3. Participants who meet DSM-5 criteria for any history of or current drug use disorder within the previous 2 years, other than cannabis, nicotine, or caffeine use disorders.
  4. Participants who consume alcohol on a regular or frequent basis and who do not agree or are deemed by the Investigator to be unable to discontinue alcohol for the duration of the study.
  5. Participants using cannabis for a physician directed medical condition requiring use such as epilepsy.
  6. Any clinically important abnormalities on Screening physical examination, assessments, electrocardiogram, or laboratory tests.
  7. Current or recent history of significant violent or suicidal behavior, risk for suicide or homicide.
  8. History of clinically significant medical condition that, in the opinion of the Principal Investigator, would jeopardize the safety of the participant or impact on the validity of the study results.
  9. Participants with risk factors for seizure.
  10. Known history of allergy, intolerance, or hypersensitivity to nabilone, gabapentin, or pregabalin.

  11. Prohibited medications at Screening:

    • Current use of narcotics, psychedelics, stimulants, opioid agonists and antagonists, kratom, illicit drugs, ketamine, unregulated psychoactive drugs (sometimes known as "gas station drugs"), or products intended to induce a feeling of being high except for cannabis
    • Regular benzodiazepine use (more than once per week) and no use within 7 days of Baseline Visit (Day 1)
    • Current use (within 7 days of Baseline Visit) of OTC products to help with sleep or anxiety
    • Prescription medications to help with sleep or anxiety within 14 days of Screening
    • Current use of nabilone, dronabinol, Sativex, Epidiolex, synthetic cannabinoids
    • Gabapentin or pregabalin or use within 30 days of Screening
  12. Heavy users of alcohol within 60 days of Screening or binge drinkers of alcohol within 30 days of Screening.
  13. A positive urine drug/alcohol test at Screening or Randomization for narcotics and/or illicit drugs other than cannabis. If the test is positive for benzodiazepines or alcohol at Screening, and if it is reported that they are only occasional users, a repeat urine drug screen can be performed at the discretion of the Medical Monitor and must be negative at the time of Randomization.
  14. Use of an investigational drug or biologic within 30 days or 5 times the half-life (whichever is longer) prior to the Screening Visit.
  15. Active influenza or COVID-19 infection or planned vaccination.
  16. Prior participation in any PleoPharma clinical study.

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Primært formål: Behandling
  • Tildeling: Randomisert
  • Intervensjonsmodell: Parallell tildeling
  • Masking: Firemannsrom

Våpen og intervensjoner

Deltakergruppe / Arm
Intervensjon / Behandling
Eksperimentell: PP-01
Oral PP-01 tapered/titrated over 34 days
Kombinasjonsprodukt: PP-01
Cannabinoid-1 (CB1) partial agonist / GABAergic modulator
Aktiv komparator: Nabilone
Oral Nabilone tapered/titrated over 34 days
Legemiddel: Nabilone
CB1 partial agonist
Placebo komparator: Placebo
Oral Placebo given daily for 34 days
Legemiddel: Placebo
Placebo komparator

Hva måler studien?

Primære resultatmål

Resultatmål
Tidsramme
AUCs of the CSCW over Days 2 to 7, inclusive, comparing PP-01 vs Placebo
Tidsramme: Days to 2 to 7
Days to 2 to 7
AUCs of the CSCW over Days 25 to 35, inclusive, comparing PP-01 vs Nabilone to assess rebound
Tidsramme: Days 25 to 35
Days 25 to 35

Sekundære resultatmål

Resultatmål
Tidsramme
AUCs of CWS-20 Irritability Domain scores over Days 2 to 35 comparing PP-01 vs Placebo
Tidsramme: Days 2 to 35
Days 2 to 35
AUCs of CWS-20 Irritability Domain scores over Days 25 to 35 comparing PP-01 vs Nabilone
Tidsramme: Days 25 to 35
Days 25 to 35
AUCs of the CSCW over Days 2 to 35 comparing PP-01 vs Placebo
Tidsramme: Days 2 to 35
Days 2 to 35
AUCs of CWS-20 Sleep Domain scores over Days 2 to 35 comparing PP-01 vs Placebo
Tidsramme: Days 2 to 35
Days 2 to 35
AUCs of CWS-20 Sleep Domain scores over Days 2 to 7 comparing PP-01 vs Placebo
Tidsramme: Days 2 to 7
Days 2 to 7
AUCs of CWS-20 Craving Domain scores over Days 2 to 35 comparing PP-01 vs Placebo
Tidsramme: Days 2 to 35
Days 2 to 35
AUCs of CWS-20 Craving Domain scores over Days 2 to 7 comparing PP-01 vs Placebo
Tidsramme: Days 2 to 7
Days 2 to 7

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Sponsor

PleoPharma, Inc.

Etterforskere

  • Studieleder: Jay Constantine, MD, PleoPharma, Inc.

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (Faktiske)

17. juni 2026

Primær fullføring (Antatt)

1. juni 2027

Studiet fullført (Antatt)

1. september 2027

Datoer for studieregistrering

Først innsendt

8. juni 2026

Først innsendt som oppfylte QC-kriteriene

8. juni 2026

Først lagt ut (Faktiske)

12. juni 2026

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

2. september 2026

Siste oppdatering sendt inn som oppfylte QC-kriteriene

1. september 2026

Sist bekreftet

1. september 2026

Mer informasjon

Begreper knyttet til denne studien

Nøkkelord

Ytterligere relevante MeSH-vilkår

Andre studie-ID-numre

  • CAN-004

Plan for individuelle deltakerdata (IPD)

Planlegger du å dele individuelle deltakerdata (IPD)?

NEI

Legemiddel- og utstyrsinformasjon, studiedokumenter

Studerer et amerikansk FDA-regulert medikamentprodukt

Ja

Studerer et amerikansk FDA-regulert enhetsprodukt

Nei

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .

Abonnere